The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase 1 study of AMG 119, a chimeric antigen receptor (CAR) T cell therapy targeting DLL3, in patients with relapsed/refractory small cell lung cancer (SCLC).
 
Lauren Averett Byers
Consulting or Advisory Role - Abbvie; Alethia Biotherapeutics; Alethia Biotherapeutics; AstraZeneca; Bristol-Myers Squibb; Genmab; LUNGevity; Medivation; PharmaMar
Research Funding - Abbvie (Inst); AstraZeneca (Inst); Genmab (Inst); Tolero Pharmaceuticals (Inst)
 
Alberto Chiappori
Consulting or Advisory Role - Abbvie; Amgen; AstraZeneca; Bristol-Myers Squibb; genentech; Novartis; PharmaMar
Speakers' Bureau - Boehringer Ingelheim; Celgene; Genentech; Merck; Takeda
Research Funding - AstraZeneca; Bristol-Myers Squibb; Novartis
 
Marie-Anne Damiette Smit
No Relationships to Disclose